- Denosumab for the treatment of osteoporosis
-
McClung MR
- KMID: 2376998
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):8-17.
- doi: 10.1016/j.afos.2017.01.002
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab
-
Chinder PS, Hindiskere S, Doddarangappa S, Pal U
- KMID: 2462566
- Clin Orthop Surg.
- 2019 Sep;11(3):352-360.
- doi: 10.4055/cios.2019.11.3.352
BACKGROUND: Giant-cell tumor of bone (GCTB) is a locally aggressive primary benign tumor presenting as an expansile osteolytic lesion affecting the epiphysis of long bones. Denosumab halts the osteolysis by... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
-
Min YK
- KMID: 2407099
- Endocrinol Metab.
- 2015 Mar;30(1):19-26.
- doi: 10.3803/EnM.2015.30.1.19
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts... -
- CITED
-
- Close
- SHARE
-
- Close
- Neurological Recovery in Two Patients with Cauda Equina Syndrome Secondary to L5 Lumbar Spine Giant Cell Tumour after Treatment with Denosumab without Surgery
-
Randhawa S, Kwan AK, Chiu CK, Chan CY, Kwan MK
- KMID: 2354822
- Asian Spine J.
- 2016 Oct;10(5):945-949.
- doi: 10.4184/asj.2016.10.5.945
We report two patients with cauda equina syndrome (CES) secondary to L5 giant cell tumour (GCT) who achieved good neurological recovery after treatment with denosumab without surgery. The first patient... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent Update on RANKL Inhibitor
-
Choi HS
- KMID: 2435162
- Korean J Med.
- 2018 Jun;93(3):252-259.
- doi: 10.3904/kjm.2018.93.3.252
The prevalence of osteoporosis is continuing to increase with growing elderly population. A variety of anti-osteoporotic agents have been used for the prevention and treatment of osteoporosis and osteoporotic fractures.... -
- CITED
-
- Close
- SHARE
-
- Close
- Cost-Effectiveness of Denosumab for Post-Menopausal Osteoporosis in South Korea
-
Bae G, Kwon HY
- KMID: 2416672
- Korean J Clin Pharm.
- 2018 Jun;28(2):131-137.
- doi: 10.24304/kjcp.2018.28.2.131
BACKGROUND: In South Korea, 22.3% of women ≥50 years of age and 37% of women ≥70 years of age visit the doctor to obtain treatment for osteoporosis. According to the... -
- CITED
-
- Close
- SHARE
-
- Close
- Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
-
Benjamin B, Benjamin M, Swe M, Sugathan S
- KMID: 2328923
- Osteoporos Sarcopenia.
- 2016 Jun;2(2):77-81.
- doi: 10.1016/j.afos.2016.03.003
OBJECTIVE: Osteoporosis is a rapidly rising cause of concern for elderly patients. Various classes of drugs are available in the market. Bisphosphonates are considered as a first-line therapy for the... -
- CITED
-
- Close
- SHARE
-
- Close
- Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor
-
Kajiwara D, Kamoda H, Yonemoto T, Iwata S, Ishii T, Tsukanishi T, Ohtori S, Yamazaki M, Okawa A
- KMID: 2382964
- Asian Spine J.
- 2016 Jun;10(3):553-557.
- doi: 10.4184/asj.2016.10.3.553
A 43-year-old male patient with C5 giant cell tumor (GCT) underwent tumor resection and anterior bone fusion of C4-C6. The tumor recurred locally 9 months after surgery with the patient... -
- CITED
-
- Close
- SHARE
-
- Close
- Dental care for patients taking antiresorptive drugs: a literature review
-
Song M
- KMID: 2463470
- Restor Dent Endod.
- 2019 Nov;44(4):e42.
- doi: 10.5395/rde.2019.44.e42
Antiresorptive drugs (ARDs), such as bisphosphonates or denosumab, that prevent bone resorption are widely used in patients with osteoporosis or with cancer that has metastasized to the bones. Although osteonecrosis... -
- CITED
-
- Close
- SHARE
-
- Close
- Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
-
Suzuki T, Nakamura Y, Kamimura M, Ikegami S, Uchiyama S, Kato H
- KMID: 2387467
- Osteoporos Sarcopenia.
- 2017 Jun;3(2):108-111.
- doi: 10.1016/j.afos.2017.03.003
OBJECTIVES: The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change
-
Nakatoh S
- KMID: 2377002
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):45-52.
- doi: 10.1016/j.afos.2016.12.001
OBJECTIVES: This study aimed to investigate the correlation between bone mineral density (BMD) and the turnover rate [√(MoMf²+ MoMr²), multiple of median formation (MoMf) was calculated as bone-specific alkaline phosphatase... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucocorticoid-induced Osteoporosis
-
Jung JY, Suh CH
- KMID: 2382653
- Korean J Med.
- 2017 Apr;92(2):142-149.
- doi: 10.3904/kjm.2017.92.2.142
Osteoporosis is a common adverse event among patients on glucocorticoid therapy. Glucocorticoids reduce bone formation and increase cortical porosity in proportion to the dose and duration of glucocorticoid use. While... -
- CITED
-
- Close
- SHARE
-
- Close
- Can denosumab be a substitute, competitor, or complement to bisphosphonates?
-
Kim SY, Ok HG, Birkenmaier C, Kim KH
- KMID: 2376043
- Korean J Pain.
- 2017 Apr;30(2):86-92.
- doi: 10.3344/kjp.2017.30.2.86
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacologic treatment of osteoporosis
-
Min YK
- KMID: 2358432
- J Korean Med Assoc.
- 2016 Nov;59(11):847-856.
- doi: 10.5124/jkma.2016.59.11.847
The objectives of this article are to review current pharmacologic approaches for the treatment of osteoporosis in Korea. Calcium and vitamin D supplementation are necessary for osteoporotic patients with inadequate... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension
-
Koh JM, Chung DJ, Chung YS, Kang MI, Kim IJ, Min YK, Oh HJ, Park IH, Lee YS, Kravitz B, Waterhouse B, Nino A, Fitzpatrick LA
- KMID: 2374122
- Yonsei Med J.
- 2016 Jul;57(4):905-914.
- doi: 10.3349/ymj.2016.57.4.905
PURPOSE: The efficacy and safety of denosumab was compared with placebo in Korean postmenopausal women with osteoporosis in this phase III study. MATERIALS AND METHODS: Women aged 60 to 90 years... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review
-
Shin YH, Shin WC, Kim JW
- KMID: 2471310
- J Bone Metab.
- 2020 Feb;27(1):15-26.
- doi: 10.11005/jbm.2020.27.1.15
A systematic search was conducted and relevant studies that evaluated the influence of osteoporosis medications (bisphosphonates [BPs], denosumab, selective estrogen receptor modulators [SERMs], recombinant human parathyroid hormone teriparatide [TPTD], and... -
- CITED
-
- Close
- SHARE
-
- Close
- New Antiresorptive Therapies for Postmenopausal Osteoporosis
-
Choi HJ
- KMID: 2201015
- J Menopausal Med.
- 2015 Apr;21(1):1-11.
- doi: 10.6118/jmm.2015.21.1.1
Osteoporosis is a systemic skeletal disease whose risk increases with age and it is common among postmenopausal women. Currently, almost all pharmacological agents for osteoporosis target the bone resorption component... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Strategy of Chemotherapy for Bone Tumors
-
Kim HS, Rha SY
- KMID: 2185084
- J Korean Orthop Assoc.
- 2015 Dec;50(6):438-443.
- doi: 10.4055/jkoa.2015.50.6.438
Despite the rarity of primary bone tumors, osteosarcoma and Ewing sarcoma are the most common primary malignant bone tumors in children and adolescents. Multiagent chemotherapy regimens for neoadjuvant and adjuvant... -
- CITED
-
- Close
- SHARE
-
- Close
- Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review
-
Walz S, Maas M, Stenzl A, Todenhöfer T
- KMID: 2471822
- World J Mens Health.
- 2020 Apr;38(2):151-163.
- doi: 10.5534/wjmh.190044
Bone health in prostate cancer patients represents a prerequisite for acceptable quality of life and optimal outcome of this disease. The major threat for bone health in prostate cancer displays... -
- CITED
-
- Close
- SHARE
-
- Close
- Current and Upcoming Treatments for Osteoporosis
-
Chung YS
- KMID: 2223113
- J Rheum Dis.
- 2012 Feb;19(1):4-10.
- doi: 10.4078/jrd.2012.19.1.4
Osteoporosis is a common senile disease that results in fragility fractures. With an ageing population, the medical and socioeconomic effect of osteoporosis, particularly postmenopausal osteoporosis, will increase further. Currently, good... -
- CITED
-
- Close
- SHARE
-
- Close
